NVCR - NovoCure GAAP EPS of -$0.36 misses by $0.07 revenue of $128.43M beats by $1.23M

• NovoCure press release ( NASDAQ: NVCR ): Q4 GAAP EPS of -$0.36 misses by $0.07 .
• Revenue of $128.43M (-3.6% Y/Y) beats by $1.23M .
• • The United States, EMEA and Japan contributed $98.6 million, $17.0 million, and $7.9 million in quarterly net revenues, respectively.
  • Net revenues were impacted by the volume of cash collections from aged claims in the U.S., the ongoing impact of German coverage updates and foreign exchange fluctuations.
  • Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $4.9 million.
• Gross margin for the quarter was 78%.
• Research, development and clinical studies expenses for the quarter were $54.8 million, a decrease of 4% from the same period in 2021.
• Sales and marketing expenses for the quarter were $49.6 million, an increase of 27% from the same period in 2021.
• General and administrative expenses for the quarter were $38.1 million, an increase of 23% from the same period in 2021.
• Adjusted EBITDA* for the quarter was $(10.5) million.
• Cash, cash equivalents and short-term investments were $969.4 million as of December 31, 2022

For further details see: